Ibandronic acid
Clinical data | |
---|---|
Trade names | Boniva, Bonviva, Bondronat, others |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 0.6% |
Protein binding | 90.9 to 99.5% (concentration-dependent) |
Metabolism | Nil |
Elimination half-life | 10 to 60 hours |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.
It was patented in 1986 by
Medical uses
Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.
Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[4]
Adverse effects
In 2008, the U.S.
Pharmacology
Bisphosphonate | Relative potency |
---|---|
Etidronate | 1 |
Tiludronate | 10 |
Pamidronate | 100 |
Alendronate | 100-500 |
Ibandronate | 500-1000 |
Risedronate | 1000 |
Zoledronate | 5000 |
Brand names
Ibandronic acid is marketed under the trade names Boniva in the US, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt, Fosfonat in Mexico.
References
- PMID 18360577.
- ISBN 9783527607495.
- ^ "Boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- S2CID 8413102.
- ^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
- S2CID 15194275.; Lay summary in: "JBMR Publishes ASBMR Task Force Report on Atypical Femoral Fractures". Journal of Bone and Mineral Research. 14 September 2010. Archived from the originalon 9 April 2016. Retrieved 27 October 2010.
- ^ "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis" (PDF). United Kingdom: The National Osteoporosis Society. Archived from the original (PDF) on 2017-06-17. Retrieved 2018-08-14.
- OCLC 868299888.
External links
- "Ibandronic acid". Drug Information Portal. U.S. National Library of Medicine.